Page Title
Drug Development Pipeline
KB001-A
Status
DiscontinuedTherapeutic Approach
Anti-Inflammatory
KB001-A is a humanized monoclonal Fab fragment that targets a Pseudomonas aeruginosa virulence factor (Type III secretion system).
Status
A phase 2 study of KB001-A was completed in 2015. No further clinical development in CF is planned at this time.
Sponsor
This program was sponsored by Kalobios Pharmaceuticals and supported by the Cystic Fibrosis Foundation. The trial was faciliated by the Therapeutics Development Network.
Recent KB001-A Studies
-
Completed with Results
Safety Study of KB001 in People with CF and Pseudomonas aeruginosa (Kalobios KB001-03)

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More